9,000 Shares in Addus HomeCare Co. (NASDAQ:ADUS) Bought by Maven Securities LTD

Maven Securities LTD acquired a new stake in Addus HomeCare Co. (NASDAQ:ADUS) during the second quarter, according to its most recent filing with the SEC. The firm acquired 9,000 shares of the company’s stock, valued at approximately $1,045,000.

Other large investors have also recently added to or reduced their stakes in the company. Trexquant Investment LP acquired a new position in Addus HomeCare during the fourth quarter worth about $271,000. US Bancorp DE lifted its position in Addus HomeCare by 177.6% during the 4th quarter. US Bancorp DE now owns 8,598 shares of the company’s stock worth $798,000 after acquiring an additional 5,501 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in Addus HomeCare during the 4th quarter valued at $5,667,000. Dean Capital Management acquired a new position in shares of Addus HomeCare in the fourth quarter worth about $652,000. Finally, Virtu Financial LLC acquired a new position in shares of Addus HomeCare in the 4th quarter valued at approximately $322,000. 95.35% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Addus HomeCare

In related news, EVP Michael D. Wattenbarger sold 21,917 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $133.29, for a total value of $2,921,316.93. Following the completion of the sale, the executive vice president now directly owns 7,215 shares of the company’s stock, valued at approximately $961,687.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Michael D. Wattenbarger sold 21,917 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the sale, the executive vice president now directly owns 7,215 shares in the company, valued at approximately $961,687.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Esteban Lopez sold 500 shares of Addus HomeCare stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $130.03, for a total value of $65,015.00. Following the transaction, the director now directly owns 3,866 shares of the company’s stock, valued at approximately $502,695.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,917 shares of company stock valued at $3,050,082. 4.60% of the stock is currently owned by company insiders.

Addus HomeCare Trading Down 3.2 %

Shares of NASDAQ ADUS opened at $128.72 on Wednesday. Addus HomeCare Co. has a 1-year low of $78.35 and a 1-year high of $136.12. The firm has a market cap of $2.33 billion, a P/E ratio of 31.94, a price-to-earnings-growth ratio of 2.40 and a beta of 1.04. The business’s 50 day moving average is $128.48 and its 200-day moving average is $115.67.

Addus HomeCare (NASDAQ:ADUS) last announced its quarterly earnings results on Monday, August 5th. The company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.21 by $0.14. Addus HomeCare had a net margin of 6.18% and a return on equity of 9.81%. The company had revenue of $286.90 million for the quarter, compared to analyst estimates of $284.90 million. During the same period in the previous year, the firm posted $0.94 EPS. The firm’s revenue was up 10.4% on a year-over-year basis. Analysts forecast that Addus HomeCare Co. will post 4.58 EPS for the current year.

Wall Street Analyst Weigh In

ADUS has been the subject of several recent research reports. TD Cowen boosted their target price on shares of Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Royal Bank of Canada reissued an “outperform” rating and set a $141.00 price objective on shares of Addus HomeCare in a research note on Tuesday, September 3rd. Oppenheimer lifted their target price on Addus HomeCare from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Monday, September 23rd. Macquarie began coverage on Addus HomeCare in a report on Friday, June 28th. They issued an “outperform” rating and a $136.00 price objective on the stock. Finally, Stephens reiterated an “overweight” rating and issued a $138.00 target price on shares of Addus HomeCare in a research note on Tuesday, August 6th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $128.29.

Addus HomeCare Company Profile

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.